NCT05622864View on ClinicalTrials.gov

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

May 7, 2025

Study Completion Date

June 16, 2025

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

HRS-9821

HRS-9821

DRUG

HRS-9821

HRS-9821

Trial Locations (1)

610044

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY